Browsing by Author "Canillas, Lidia"

Sort by: Order: Results:

  • Clinical guideline on perioperative management of patients with advanced chronic liver disease
    Canillas, Lidia; Pelegrina Manzano, Amalia; Álvarez, Juan C.; Colominas-González, Elena; Salar, Antonio; Aguilera, Lluís G.; Burdío Pinilla, Fernando; Montes, Antonio; Grau, Santiago; Grande, Luís; Carrión Rodríguez, José Antonio (MDPI, 2023)
    (1) Background: Patients with advanced chronic liver disease (ACLD) are living longer with more comorbidities because of improved medical and surgical management. However, patients with ACLD are at increased risk of ...
  • Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection
    Canillas, Lidia; Broquetas, Teresa; Carrión Rodríguez, José Antonio; Pagano, Giulia; Soriano, Agnès; Garrido, Esther; Fernández, Rosa; Viu, Ana; Romero, Judit; Díaz,Gemma; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Naranjo‐Hans, Dolores; Bessa Caserras, Xavier; Garcia-Retortillo, Montserrat; Puigvehí, Marc (Wiley, 2022)
    Abnormal liver function tests (A-LFTs) during admission for coronavirus disease-19 (COVID-19) are frequent, but its evolution after COVID-19 resolution remains unexplored. We evaluated factors related to A-LFTs during ...
  • Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients
    Broquetas, Teresa; Garcia-Retortillo, Montserrat; Micó, Miquel; Canillas, Lidia; Puigvehí, Marc; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Viu, Ana; Hernández, Juan José; Bessa Caserras, Xavier; Carrión Rodríguez, José Antonio (Baishideng Publishing Group, 2020)
    Background: Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues (NAs) rarely achieve hepatitis B surface antigen (HBsAg) loss. Aim: To evaluate if the addition of pegylated interferon ...
  • On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
    Broquetas, Teresa; Hernández, Juan José; Garcia-Retortillo, Montserrat; Canillas, Lidia; Puigvehí, Marc; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Viu, Ana; Garrido, Esther; Micó, Miquel; Bessa Caserras, Xavier; Carrión Rodríguez, José Antonio (Elsevier, 2022)
    Background: Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established. Aims: to evaluate the impact of HBsAg kinetics before treatment interruption on ...
  • Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
    Soria, Anna; Calvo, Mariona; Casas, Meritxell; Vidales, Zara; Muñoz-Martínez, Sergio; Sapena, Victor; Puigvehí, Marc; Canillas, Lidia; Guardeño, Raquel; Gallego, Adolfo; Mínguez, Beatriz; Horta, Diana; Clos, Ariadna; Montoliu, Silvia; Roget, Mercè; Reig, María; Vergara, Mercè (Frontiers, 2022)
    Introduction: the first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking